annamycin

annamycin

Oncology A liposomal anthracycline for treating CAs–eg multiple-drug-resistant tumors–eg, refractory breast CA, refractory/relapsed AML, ALL, blast crisis of CML. See Anthracycline, Liposomes.
References in periodicals archive ?
L- Annamycin, a member of the anthracycline family of proven anti-cancer drugs, has a novel therapeutic profile, including potential activity against multi- drug resistant tumors and significantly reduced cardiotoxicity, or damage to the heart, compared to currently available drug alternatives.
Callisto initiated a clinical trial of L- Annamycin in adult relapsed or refractory acute lymphoblastic leukemia patients in 4Q 2005.
L- Annamycin, a new compound from the anthracycline family of proven anti-cancer drugs, has a novel therapeutic profile, including activity against resistant diseases and significantly reduced cardiotoxicity, or damage to the heart, compared to currently available drug alternatives.
Callisto has been conducting a well-controlled study using single-agent L- Annamycin in the treatment of adults with relapsed or refractory acute ALL to confirm the maximum tolerated dose (MTD) reported from the previous sponsor.
Callisto initiated a clinical trial of L- Annamycin in pediatric acute leukemia patients in 1Q 2007 and initiated a trial in adult relapsed or refractory acute lymphoblastic leukemia patients in 4Q 2005.